Buchang Pharma associate lists on Nasdaq; subsidiary gets drug approval

Shandong Buchang Pharmaceuticals Co., Ltd. announced that its associate, Guangzhou 7LK Digital Health Technology Co., Ltd., through its indirectly controlled entity POMDOCTOR LIMITED, began trading on Nasdaq on October 8, 2025, under the ticker symbol POM. Following the global offering, Buchang Pharmaceuticals holds approximately 15% of the total share capital through its wholly-owned subsidiary Dan Hong (H.K.) Technology Limited. This listing is expected to positively impact Buchang’s 2025 financial performance.

In a separate announcement, Buchang Pharmaceuticals also confirmed that its wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., received a drug registration certificate for Ibuprofen Sustained-Release Capsules from the National Medical Products Administration. This non-prescription drug is valid until September 29, 2030, and is approved for pain relief and fever reduction.

The company has invested approximately RMB1206.18 in research and development for Ibuprofen Sustained-Release Capsules. This approval enhances Buchang's product portfolio and ensures stable production capacity to meet market demand, positively impacting future operations.